Peptilogics
Peptilogics’ clinical stage pipeline is led by PLG0206, a novel anti-biofilm therapeutic, currently enrolling the pivotal Ph2/3 RETAIN trial for the treatment of devastating prosthetic joint infections (PJI), for which there are no approved therapies. PLG0206 has Orphan Disease Designation from the FDA, Fast Track and QIDP status. Restoring Function Saving LivesWe are dedicated to curing and preventing medical device-related infection – a devastating and, too often, life-threatening condition af
Basic Information
- Category: business
- Website: https://www.peptilogics.com/
Documented Facts
- Headquarters location (Wikidata; date unspecified): Pittsburgh (Source 3: Wikidata Q108756914, revision 1519768614; Source 4: Wikidata label: Q1342, revision 2530079495)
- Country (Wikidata; date unspecified): United States (Source 3: Wikidata Q108756914, revision 1519768614; Source 5: Wikidata label: Q30, revision 2556188301)
Evidence and Sources
- Peptilogics — Official Site (official)
- Peptilogics on linkedin (social)
- Wikidata Q108756914, revision 1519768614 (knowledge-base)
- Wikidata label: Q1342, revision 2530079495 (knowledge-base)
- Wikidata label: Q30, revision 2556188301 (knowledge-base)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Peptilogics.
- Canonical profile: https://brandsource.ai/brands/peptilogics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/peptilogics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/peptilogics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (88/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-21
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
Peptilogics’ clinical stage pipeline is led by PLG0206, a novel anti-biofilm therapeutic, currently enrolling the pivotal Ph2/3 RETAIN trial for the treatment of devastating prosthetic joint infections (PJI), for which there are no approved therapies. PLG0206 has Orphan Disease Designation from the FDA, Fast Track and QIDP status. Restoring Function Saving LivesWe are dedicated to curing and preventing medical device-related infection – a devastating and, too often, life-threatening condition af
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 4 supporting sources linked.
- 2 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.